{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:51:12Z","timestamp":1793994672866,"version":"4.8.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.blre.2023.101112","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T01:01:05Z","timestamp":1688000465000},"page":"101112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Primary and secondary immune thrombocytopenia (ITP): Time for a rethink"],"prefix":"10.1016","volume":"61","author":[{"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Provan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abelardo","family":"B\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Bernardo-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mart\u00ednez-Carballeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Jim\u00e9nez-B\u00e1rcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Fern\u00e1ndez-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.blre.2023.101112_bb0005","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOP.0b013e32834ea739","article-title":"New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome","volume":"24","author":"Teachey","year":"2012","journal-title":"Curr Opin Pediatr"},{"issue":"22","key":"10.1016\/j.blre.2023.101112_bb0015","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2023.101112_bb0020","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM198904133201505","article-title":"Mechanisms of response to treatment in autoimmune thrombocytopenic purpura","volume":"320","author":"Gernsheimer","year":"1989","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.blre.2023.101112_bb0035","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.blre.2023.101112_bb0040","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101112_bb0050","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.V95.8.2523","article-title":"Acute onset hemoglobinemia and\/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients","volume":"95","author":"Gaines","year":"2000","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0055","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26040","article-title":"High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia","volume":"96","author":"Roumier","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101112_bb0065","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1002\/ajh.24341","article-title":"Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study","volume":"91","author":"Zaja","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.15280","article-title":"Romiplostim for the management of perioperative thrombocytopenia","volume":"182","author":"Al-Samkari","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0075","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1055\/s-0038-1677531","article-title":"Peri-operative eltrombopag or immune globulin for patients with immune thrombocytopaenia (the bridging ITP trial): methods and rationale","volume":"119","author":"Arnold","year":"2019","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101112_bb0080","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminhematol.2016.04.010","article-title":"Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?","volume":"53","author":"Schifferli","year":"2016","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0085","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/09537104.2019.1624709","article-title":"Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)","volume":"31","author":"Kapur","year":"2020","journal-title":"Platelets"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0090","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0091270010375427","article-title":"Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura","volume":"51","author":"Gibiansky","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0095","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/0091270010383019","article-title":"Population PK\/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing","volume":"51","author":"Hayes","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101112_bb0110","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101112_bb0115","author":"U.S. Food and Drug Administration"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0120","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.exphem.2009.06.011","article-title":"Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function","volume":"37","author":"Erhardt","year":"2009","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/2040620712442525","article-title":"Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile","volume":"3","author":"Cheng","year":"2012","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0130","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2023.101112_bb0135","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01198.x","article-title":"AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist","volume":"82","author":"Fukushima-Shintani","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101112_bb0145","series-title":"Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers","author":"Desjardins","year":"2006"},{"issue":"25","key":"10.1016\/j.blre.2023.101112_bb0150","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.blre.2023.101112_bb0175","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06339.x","article-title":"An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura","volume":"135","author":"Newland","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.2010.08140.x","article-title":"Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside","volume":"150","author":"Molineux","year":"2010","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0190","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0195","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1538-7836.2010.03830.x","article-title":"Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)","volume":"8","author":"Gernsheimer","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0200","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12185-012-1088-8","article-title":"Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care","volume":"96","author":"Stasi","year":"2012","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0205","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12185-015-1889-7","article-title":"Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia","volume":"103","author":"Park","year":"2016","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101112_bb0215","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2016.161968","article-title":"Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia","volume":"102","author":"Cines","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0220","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000381657","article-title":"Romiplostim treatment in adults with immune thrombocytopenia of varying duration and severity","volume":"134","author":"Janssens","year":"2015","journal-title":"Acta Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0225","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12185-015-1837-6","article-title":"Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim","volume":"102","author":"Cines","year":"2015","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101112_bb0235","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101112_bb0240","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.blre.2023.101112_bb0245","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2023.101112_bb0250","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.blre.2023.101112_bb0255","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0265","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"issue":"9978","key":"10.1016\/j.blre.2023.101112_bb0270","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0275","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia","volume":"119","author":"Arnold","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2023.101112_bb0280","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.mayocp.2019.05.024","article-title":"Sequence of splenectomy and rituximab for the treatment of steroid-refractory immune thrombocytopenia: does it matter?","volume":"94","author":"Hammond","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.15090","article-title":"A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP","volume":"181","author":"Rodeghiero","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0290","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.26378","article-title":"Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment","volume":"97","author":"Mageau","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0295","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.21029","article-title":"Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century","volume":"83","author":"Dolan","year":"2008","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0300","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00277-018-3232-x","article-title":"Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia","volume":"97","author":"Togasaki","year":"2018","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101112_bb0305","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2023.101112_bb0310","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0315","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2141.2002.03709.x","article-title":"High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura","volume":"118","author":"Levy","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0320","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.226688","article-title":"Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia","volume":"105","author":"Zhang","year":"2020","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.blre.2023.101112_bb0325","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4(+) T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2023.101112_bb0330","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0335","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.22211","article-title":"Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIb\u03b1 antibodies","volume":"87","author":"Zeng","year":"2012","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.blre.2023.101112_bb0340","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/bloodadvances.2017010942","article-title":"Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP registry","volume":"1","author":"Arnold","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0345","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN guidelines\u00ae insights: myelodysplastic syndromes, version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2023.101112_bb0350","series-title":"Bone marrow failure. StatPearls. Treasure Island (FL): statpearls publishing copyright \u00a9 2022","author":"Moore","year":"2022"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0355","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jth.12196","article-title":"Inherited thrombocytopenias frequently diagnosed in adults","volume":"11","author":"Balduini","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0360","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/ajh.25379","article-title":"Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data","volume":"94","author":"Mitta","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101112_bb0365","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0370","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11882-014-0462-4","article-title":"Autoimmune lymphoproliferative syndrome: an update and review of the literature","volume":"14","author":"Shah","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"12","key":"10.1016\/j.blre.2023.101112_bb0375","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0380","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/ejh.13144","article-title":"Immune thrombocytopenia: effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment","volume":"101","author":"Chang","year":"2018","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0385","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V85.2.351.351","article-title":"Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura","volume":"85","author":"Reiner","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0390","first-page":"2137","article-title":"Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura","volume":"17","author":"Wang","year":"2019","journal-title":"Exp Ther Med"},{"issue":"11","key":"10.1016\/j.blre.2023.101112_bb0395","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00277-016-2791-y","article-title":"Cyclosporin A for persistent or chronic immune thrombocytopenia in children","volume":"95","author":"Liu","year":"2016","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0400","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000206184","article-title":"Danazol in idiopathic thrombocytopenic purpura","volume":"74","author":"Almagro","year":"1985","journal-title":"Acta Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187296","article-title":"Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: a retrospective study of 42 patients","volume":"12","author":"Est\u00e8ve","year":"2017","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0410","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0415","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF01728791","article-title":"Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases","volume":"60","author":"Fenaux","year":"1990","journal-title":"Blut"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0420","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12185-015-1903-0","article-title":"Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study","volume":"103","author":"Park","year":"2016","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0425","article-title":"Treatments for primary immune thrombocytopenia: a review","volume":"11","author":"Samson","year":"2019","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.blre.2023.101112_bb0430","article-title":"Immune thrombocytopenia (ITP): current limitations in patient management","volume":"56","author":"Terrell","year":"2020","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0435","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","article-title":"A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0440","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2015-03-631937","article-title":"A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)","volume":"126","author":"Choi","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0445","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2009-06-222448","article-title":"Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura","volume":"115","author":"Arnold","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0450","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12185-012-1124-8","article-title":"A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia","volume":"96","author":"Wang","year":"2012","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30170-9","article-title":"Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial","volume":"4","author":"Feng","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0460","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/bjh.17872","article-title":"Novel therapies for immune thrombocytopenia","volume":"196","author":"Kuter","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0465","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000517989","article-title":"The mechanistic effects and clinical applications of various derived mesenchymal stem cells in immune thrombocytopenia","volume":"145","author":"He","year":"2022","journal-title":"Acta Haematol"},{"issue":"22","key":"10.1016\/j.blre.2023.101112_bb0470","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0475","article-title":"Avances en el conocimiento y manejo del s\u00edndrome linfoproliferativo autoinmune","volume":"80","author":"Garrido","year":"2014","journal-title":"Anales de Pediatr\u00eda"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0480","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0485","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/BOR.0000000000000599","article-title":"Treatment of primary and secondary immune thrombocytopenia","volume":"31","author":"Kado","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0490","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2023.101112_bb0495","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2016.07.001","article-title":"The diagnosis and management of the haematologic manifestations of lupus","volume":"74","author":"Velo-Garc\u00eda","year":"2016","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0500","doi-asserted-by":"crossref","first-page":"20","DOI":"10.31138\/mjr.28.1.20","article-title":"Lupus thrombocytopenia: pathogenesis and therapeutic implications","volume":"28","author":"Galanopoulos","year":"2017","journal-title":"Mediterr J Rheumatol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0505","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0510","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2023.101112_bb0515","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0520","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u2018extra-criteria\u2019 manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0525","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-014-0494-8","article-title":"The significance and management of thrombocytopenia in antiphospholipid syndrome","volume":"17","author":"Artim-Esen","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091170","article-title":"Immune thrombocytopenia in antiphospholipid syndrome: is it primary or secondary?","volume":"9","author":"Tomasello","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0535","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The European society for immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2023.101112_bb0540","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fimmu.2012.00189","article-title":"Autoimmune cytopenias in common variable immunodeficiency","volume":"3","author":"Podjasek","year":"2012","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0545","first-page":"670","article-title":"Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review","volume":"16","author":"Durani","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101112_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071532","article-title":"Autoimmune complications in hematologic neoplasms","volume":"13","author":"Barcellini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1 Suppl 2","key":"10.1016\/j.blre.2023.101112_bb0555","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"Cines","year":"2009","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0560","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-019-0838-7","article-title":"Immune-mediated cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies","volume":"21","author":"Michniacki","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0565","first-page":"599","article-title":"The role of B cell-activating factor secreted by peripheral blood monocyte-derived dendritic cell in chronic idiopathic thrombocytopenic purpura","volume":"31","author":"Zhou","year":"2010","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"10.1016\/j.blre.2023.101112_bb0570","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood.V85.5.1282.bloodjournal8551282","article-title":"Involvement of CD31 in lymphocyte-mediated immune responses: importance of the membrane-proximal immunoglobulin domain and identification of an inhibiting CD31 peptide","volume":"85","author":"Zehnder","year":"1995","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2023.101112_bb0580","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia","volume":"367","author":"Afdhal","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0585","first-page":"234","article-title":"Thrombosis associated with viral hepatitis","volume":"2","author":"Galli","year":"2014","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0590","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/2325957414557266","article-title":"Initial experience with the use of thrombopoetin receptor agonists in patients with refractory HIV-associated immune thrombocytopenic purpura: a case series","volume":"14","author":"Kowalczyk","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"11","key":"10.1016\/j.blre.2023.101112_bb0595","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s42399-020-00521-8","article-title":"Immune thrombocytopenia secondary to COVID-19: a systematic review","volume":"2","author":"Bhattacharjee","year":"2020","journal-title":"SN Compr Clin Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0600","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.18686","article-title":"Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - a monocentric analysis","volume":"201","author":"Schaefers","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0605","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjh.16775","article-title":"Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic","volume":"189","author":"Pavord","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0610","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3324\/haematol.2008.005348","article-title":"Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review","volume":"94","author":"Arnold","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0615","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/hel.12200","article-title":"Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography","volume":"20","author":"Frydman","year":"2015","journal-title":"Helicobacter"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0620","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0625","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-0039-1697930","article-title":"Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics","volume":"46","author":"Danese","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2023.101112_bb0630","author":"Platelets on the Web"},{"issue":"3","key":"10.1016\/j.blre.2023.101112_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25379","article-title":"Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data","volume":"94","author":"Mitta","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101112_bb0640","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/asheducation-2009.1.153","article-title":"Drug-induced thrombocytopenia: pathogenesis, evaluation, and management","author":"George","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2023.101112_bb0645","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of heparin-induced thrombocytopenia","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.blre.2023.101112_bb0650","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/asheducation-2013.1.668","article-title":"Heparin-induced thrombocytopenia","volume":"2013","author":"Lee","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.blre.2023.101112_bb0655","doi-asserted-by":"crossref","first-page":"841","DOI":"10.7196\/SAMJ.2021.v111i9.15909","article-title":"Heparin-induced thrombocytopenia: an update for the COVID-19 era","volume":"111","author":"Bailly","year":"2021","journal-title":"S Afr Med J"},{"issue":"9396","key":"10.1016\/j.blre.2023.101112_bb0660","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","article-title":"Vaccination and autoimmune disease: what is the evidence?","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.blre.2023.101112_bb0665","article-title":"Vaccines for measles, mumps, rubella, and varicella in children","volume":"11","author":"Di Pietrantonj","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.blre.2023.101112_bb0670","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.jemermed.2012.01.060","article-title":"A case of Evans\u2019 syndrome following influenza vaccine","volume":"44","author":"Shlamovitz","year":"2013","journal-title":"J Emerg Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101112_bb0675","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101112_bb0680","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood.2021013411","article-title":"SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP","volume":"139","author":"Lee","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0685","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1002\/ajh.24705","article-title":"Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia","volume":"92","author":"Lambert","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101112_bb0690","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH13-10-0873","article-title":"Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia","volume":"112","author":"Alvarez Rom\u00e1n","year":"2014","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.blre.2023.101112_bb0695","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s12325-022-02133-1","article-title":"Proposal for a new protocol for the management of immune thrombocytopenia (ITP)","volume":"39","author":"Gonz\u00e1lez-L\u00f3pez","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101112_bb0700","article-title":"Current concepts in the diagnosis and management of adult primary immune thrombocytopenia: our personal view","volume":"59","author":"Gonz\u00e1lez-L\u00f3pez","year":"2023","journal-title":"Medicina (Kaunas)"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:34:04Z","timestamp":1724772844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":139,"alternative-id":["S0268960X23000735"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101112","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary and secondary immune thrombocytopenia (ITP): Time for a rethink","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101112"}}